EMBRYO BIOPSY AND MATERNAL AND NEONATAL OUTCOMES FOLLOWING CRYOPRESERVED-THAWED SINGLE EMBRYO TRANSFER

Background: Contemporary embryo biopsy in the United States involves removal of several cells from a blastocyst that would become the placenta for preimplantation genetic testing (PGT). Embryos are then cryopreserved while patients await biopsy results, with transfers occurring in a subsequent cycle as a single frozen-thawed embryo transfer, if euploid. Objective: We sought to determine if removal of these cells for PGT was associated with adverse obstetrical or neonatal outcomes following frozen-thawed single embryo transfer. Study design: We linked ART surveillance data from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System (SART CORS) to birth certificates and maternal and neonatal hospitalization discharge diagnoses in Massachusetts from 2014-2017, considering only singleton births following autologous frozen-thawed single embryo transfers. We compared outcomes of cycles having embryo biopsy (n=585) to those having no biopsy (n=2,191), using Chi-square for categorical and binary variables, and logistic regression for adjusted odds ratios (aOR\u27s) and 95% confidence intervals, adjusting for mother\u27s age, race, education, parity, BMI, birth year, insurance, and all infertility diagnoses. Results: Considering no biopsy as the reference, there were no differences between groups with respect to preeclampsia (aOR =0.82, 0.42-1.61, p=0.5685); pregnancy-induced hypertension (aOR = 0.85, 0.46-1.59, p=0.6146); placental disorders including abruption, previa, accreta, increta and percreta (aOR=1.16, 0.60-2.24, p=0.6675); preterm birth (aOR=1.22, p=0.73-2.03, p=0.4418); low birth weight (aOR=1.12, p=0.58-2.15, p=0.7355); cesarean section delivery (aOR=1.04, p=0.79-1.38, p=0.7762); or gestational diabetes mellitus (aOR=0.83, 0.50-1.38, p=0.4734). In addition, there were no differences between groups for prolonged hospital stay for mothers (aOR=1.23, 0.83-1.80, p=0.3014) or for infants (aOR=1.29, 0.72-2.29, p=0.3923). Conclusions: Embryo biopsy for preimplantation genetic testing does not increase the odds for diagnoses related to placentation (preeclampsia, pregnancy-related hypertension, placental disorders, preterm delivery, or low birth weight), maternal conditions (gestational diabetes), or maternal or infant length of stay following delivery